Tol­er­ance Bio emerges from stealth with $17.2M to ad­vance ther­a­pies de­vel­oped from the thy­mus

Tol­er­ance Bio has launched with an over­sub­scribed $17.2 mil­lion seed round and a goal to de­vel­op ther­a­pies for im­mune-me­di­at­ed dis­eases, from can­cer to trans­plant re­jec­tion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER